The MWAN Experience In Scaling-Up HPV Vaccination In Nigeria: Challenges, Lessons Learned, And Future Directions
Main Article Content
Abstract
Background: cervical cancer remains a major public health concern in Nigeria due to low HPV vaccine coverage and limited access to screening and treatment. In response, the Nigerian FMOH launched a three-phase nationwide rollout of free routine HPV vaccination targeting girls aged 9 to 14 years; however, the initial phase encountered considerable hesitancy and rejections.
Objective: this paper examines the proactive steps taken by the Medical Women's Association of Nigeria (MWAN) to ensure successful implementation during the Phase-2 rollout and subsequent routine phase.
Methods: MWAN employed a multifaceted strategy integrating robust advocacy, targeted community engagement, and strategic collaborations with key stakeholders—including IVAC, DCL, Paediatric Association of Nigeria, Pathfinder, NPHCDA, SPHCDA, and various CSOs. This approach involved comprehensive stakeholder engagement, capacity building for healthcare workers, extensive public enlightenment, community mobilization, technical support, and continuous knowledge-sharing initiatives.
Key Findings: collaborative efforts resulted in the training of 30 MWAN members, 34 CSOs, 17 youth leaders, and 493 community-based HPV Vaccine Champions across 21 Phase-2 states. In addition, 695 medical practitioners were engaged to promote HPV vaccine uptake through clinical practice. Vaccine coverage improved markedly in Phase 2, rising to 96% from 80% in Phase 1. Challenges—including misinformation, distrust in government and health systems, resistance from educational and religious leaders, healthcare workforce training gaps, and cultural barriers—were effectively addressed through positive information dissemination, targeted re-sensitization, and the use of HPV ambassadors. Key lessons include the critical importance of early stakeholder engagement and leveraging peer networks to drive awareness and acceptance.
Conclusion: MWAN's strategic interventions advanced the HPV vaccination rollout in Nigeria and offer a replicable model for effective immunization programs. Sustained collaboration among government agencies, NGOs, media, and community leaders is essential to overcoming vaccination barriers and reducing the burden of cervical cancer nationwide.
Downloads
Article Details

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
Nyiramana MP. Cervical Cancer Prevention and Women’s Well-Being in Nigeria: A Comprehensive Review. 2024; 3(3):22–6. doi: 10.59298/rijpp/2024/332226
Lawal QO, Lawal IK, Carter CS, Khan S. Cervical Cancer Burden in Nigeria: Review of Current Situation. Gynecol Reprod Health. 2023; 7(1): 1-5. doi: 10.33425/2639-9342.1211.
Global Alliance for Vaccines and Immunization (GAVI). Nigeria to vaccinate 7.7 million girls against leading cause of cervical cancer [Internet]. 2023 Oct 24 [cited 2025 Mar 1]. Available from: https://www.gavi.org/news/media-room/nigeria-vaccinate-77-million-girls-against-leading-cause-cervical-cancer
World Health Organization (WHO). Nigeria to vaccinate 7.7 million girls against leading cause of cervical cancer [Internet]. 2023 Oct 24 [cited 2025 Mar 1]. Available from: https://www.afro.who.int/countries/nigeria/news/nigeria-vaccinate-77-million-girls-against-leading-cause-cervical-cancer
World Health Organization (WHO). Cervical cancer: key facts [Internet]. 2023 [cited 2025 Mar 5]. Available from: https://www.who.int/news-room/fact-sheets/detail/cervical-cancer
Halemani K, Sannamma JS. Advancements in HPV Vaccination for Cervical Cancer Prevention: A Comprehensive Review. Saudi journal of nursing and health care 2024; 122-3. doi: 10.36348/sjnhc.2024.v07i05.002.
Lowy DR, Schiller JT. Reducing HPV-associated cancer globally. Cancer Prev Res (Phila). 2012;5(1):18-23. doi:10.1158/1940-6207.CAPR-11-0542
World Health Organization (WHO). Global strategy to accelerate the elimination of cervical cancer as a public health problem [Internet]. 2020 [cited 2025 Mar 10]. Available from: https://www.who.int/publications/i/item/9789240014107
González-Rodríguez JC, Cruz-Valdez A, Madrid-Marina V. Cervical cancer prevention by vaccination: review. Front Oncol. 2024; 3;14:1386167. doi: 10.3389/fonc.2024.1386167. PMID: 38715779; PMCID: PMC11075630.
Duru CG, Ugochukwu EF1. Onubogu CU, Ushie SN, Mbachu CNP. The state of human papillomavirus (HPV) vaccination among secondary school adolescents in Nnewi, Nigeria prior to free routine HPV vaccine rollout. Niger J Paediatr. 2014; 51(3): 241-50
Azuogu BN, Umeokonkwo CD, Azuogu VC, Onwe OE, Okedo-Alex IN, Egbuji CC. Appraisal of willingness to vaccinate daughters with human papillomavirus vaccine and cervical cancer screening uptake among mothers of adolescent students in Abakaliki, Nigeria. Niger J Clin Pract. 2019; 22(9):1286-1291.https://doi.org/10.4103/njcp.njcp_452_1
Medical Women's Association of Nigeria (MWAN). MWAN: Who we are [Internet]. [cited 2025 Feb. 26]. Available from: https://www.mwan.org/
Medical Women's International Association (MWIA). Report June 2024 – Nigeria [Internet]. [cited 2025 Feb 12]. Available from: https://mwia.net/2024/08/27/report-june-2024-nigeria/